UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

UBS initiated buy coverage of Viking Therapeutics (VKTX) with a $94 price target, implying 250% upside from current levels. The clinical-stage biotech's experimental weight loss drug VK2735 has shown promising results, potentially delivering twice the weight loss of semaglutide and 1.5x that of tirzepatide. Viking is advancing both injectable and oral formulations into phase 3 trials and raised $575 million in September to fund development, though the company faces competition from established players and regulatory risks.